Roche Holding AG (RHHVF)
289.09
-5.79
(-1.96%)
USD |
OTCM |
Nov 14, 16:00
Roche Debt to Equity Ratio: 1.19 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.19 |
| December 31, 2023 | 0.9964 |
| June 30, 2023 | 0.9574 |
| December 31, 2022 | 0.9057 |
| June 30, 2022 | 1.102 |
| December 31, 2021 | 1.274 |
| June 30, 2021 | 0.397 |
| December 31, 2020 | 0.3912 |
| June 30, 2020 | 0.4774 |
| December 31, 2019 | 0.4386 |
| June 30, 2019 | 0.6975 |
| December 31, 2018 | 0.6795 |
| June 30, 2018 | 0.7576 |
| December 31, 2017 | 0.7171 |
| June 30, 2017 | 0.9254 |
| December 31, 2016 | 0.9349 |
| June 30, 2016 | 1.344 |
| December 31, 2015 | 1.108 |
| Date | Value |
|---|---|
| June 30, 2015 | 1.409 |
| December 31, 2014 | 1.313 |
| June 30, 2014 | 1.095 |
| December 31, 2013 | 0.9663 |
| June 30, 2013 | 1.532 |
| December 31, 2012 | 1.694 |
| June 30, 2012 | 2.761 |
| December 31, 2011 | 2.216 |
| June 30, 2011 | 2.970 |
| December 31, 2010 | 3.174 |
| June 30, 2010 | 6.578 |
| December 31, 2009 | 5.758 |
| June 30, 2009 | 15.36 |
| December 31, 2008 | 0.0919 |
| June 30, 2008 | 0.1343 |
| December 31, 2007 | 0.151 |
| June 30, 2007 | 0.1799 |
| December 31, 2006 | 0.2085 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.3912
Minimum
Dec 2020
1.274
Maximum
Dec 2021
0.8129
Average
0.9315
Median
Debt to Equity Ratio Benchmarks
| AC Immune SA | 0.00 |
| CRISPR Therapeutics AG | -- |
| Addex Therapeutics Ltd | 0.00 |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 106.56B |
| Total Liabilities (Quarterly) | 69.98B |
| Shareholders Equity (Quarterly) | 32.20B |
| Current Ratio | 1.264 |
| Net Debt Paydown Yield | -1.66% |